Shire plc (ADR) (NASDAQ:SHPG)

462542665

Just How Expensive Is the Pharmacyclics Buyout?

Pharmacyclics Inc. (NASDAQ: PCYC) has seen its stock surge in the past week as rumors swirl about a potential acquisition. News finally broke late Wednesday that there was an official ...
Read Full Story »
Pills

Analyst’s 8 Top Health Care Stocks for 2015

Health care had an outstanding year in 2014. In fact the sector through last Friday was up 23.30%, which placed it third in the S&P 500 sector race, just behind ...
Read Full Story »
Pills

5 Top Pharmaceutical Stock Picks for 2015

After an outstanding 2014, the health care sector could be primed for yet another solid performance in 2015. While many analysts on Wall Street are very positive on the group, ...
Read Full Story »
investor research

Top Analyst Upgrades and Downgrades: Cisco, DreamWorks, Lululemon, Nabors, Schlumberger, Verizon and More

Stocks were indicated much lower on Tuesday as the market is dealing with lower commodities (oil and more) and a weak China and Europe. What has been proven repeatedly in ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Apple, BHP, Ford, GM, IBM, NetEase, Shire and More

Stocks were firm again on Tuesday morning. Investors have now formally proven yet again that they are willing to buy value and overlooked stocks on the dips. 24/7 Wall St. ...
Read Full Story »
investing

Jefferies Has 5 Stocks to Buy With Big Catalysts This Week

With earnings season in full force this week, the presentation of quarterly numbers will likely drive the direction of many stocks. Despite a huge turnaround by the markets on Friday, ...
Read Full Story »
investing

3 Crowded Stocks Down Almost 40% That Could Bounce Back for Huge Gains

Everything in the stock market is getting hit hard, even the so-called safe stocks like Apple, Walmart and Disney are getting taken down. When you have stocks that have been ...
Read Full Story »
Tax

Is Treasury Plan for Tax Inversion REALLY Trouble for Merger Stocks?

The U.S. Treasury has finally made its proposed effort to deal with the waves of corporate tax inversions that have created such a stir of late. The move is also ...
Read Full Story »
Pills

AbbVie Earnings Take Back Seat to Shire Merger

AbbVie Inc. (NYSE: ABBV) reported second-quarter 2014 results before markets opened Friday. The pharmaceutical research firm posted adjusted diluted earnings per share (EPS) of $0.82 on revenues of $4.93 billion. ...
Read Full Story »
Pills

Jefferies Initiates Coverage on Specialty Pharmaceutical Takeover Candidates

The specialty pharmaceutical sector is exploding with news of takeovers, exchanges and possible mergers. The biggest is the possible deal between activist hedge fund manager Bill Ackman's Pershing Square, Valeant ...
Read Full Story »
Samuel Beckett Bridge

Are Biotech Stocks Located in Ireland Top Buyout Candidates?

St. Patrick's Day may have come and gone for this year, but some of the biotechnology stocks that are domiciled in Ireland might just be getting ready for the party. ...
Read Full Story »
investor research

Top Analyst Upgrades and Downgrades: eBay, NBG, Petrobras, Twitter and More

Stocks have had gains for eight weeks now and the stock market keeps challenging all-time highs. It is time for investors to start positioning their assets and portfolios for 2014. ...
Read Full Story »
Pills

Shire, Novartis Deals: Pharmaceutical Shakeups Continue

The wave of mergers and acquisitions in health care continues with two big announcements Monday. Drug maker Shire PLC (NASDAQ: SHPG) will acquire the rare disease biopharmaceutical company ViroPharma (NASDAQ: ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Ariad, Hecla, HP, Micron and More

Earnings season has officially started, but the stock market and bond market are both dealing with the government shutdown, an upcoming debt ceiling and even the announcement of a new ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: CIT, Intel, Nike, J.C.Penney and More

As a government shutdown and debt ceiling debate rage on as new (or repetitive) market risks, investors have to decide which stocks to buy and which to sell or avoid. ...
Read Full Story »